Details of the Drug Combination

General Information of Drug Combination (ID: DCURWEF)

Drug Combination Name
Gemcitabine PHA848125
Indication
Disease Entry Status REF
Diffuse intrinsic pontine glioma Investigative [1]
Component Drugs Gemcitabine   DMSE3I7 PHA848125   DMS2Q9G
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: DIPG25
Zero Interaction Potency (ZIP) Score: 16.288
Bliss Independence Score: 17.995
Loewe Additivity Score: 5.67
LHighest Single Agent (HSA) Score: 7.933

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Gemcitabine
Disease Entry ICD 11 Status REF
Anterior urethra cancer N.A. Approved [2]
Biliary tract cancer 2C17 Approved [2]
Carcinoma 2A00-2F9Z Approved [2]
Cervical cancer 2C77.0 Approved [2]
Cholangiocarcinoma 2C12.10 Approved [2]
Fallopian tube neoplasm N.A. Approved [2]
Gallbladder carcinoma N.A. Approved [2]
Leiomyosarcoma 2B58 Approved [2]
Leukemia N.A. Approved [2]
Lung cancer 2C25.0 Approved [2]
MALT lymphoma N.A. Approved [2]
Nodal marginal zone lymphoma 2A85.0 Approved [2]
Non-small-cell lung cancer 2C25 Approved [3]
Ovarian disorder N.A. Approved [2]
Ovarian neoplasm N.A. Approved [2]
Pancreatic adenocarcinoma N.A. Approved [2]
Pancreatic ductal carcinoma 2C10.0 Approved [2]
Pancreatic tumour 2C10 Approved [2]
Posterior urethra cancer N.A. Approved [2]
Recurrent adult burkitt lymphoma 2A85.6 Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [4]
Splenic marginal zone lymphoma N.A. Approved [2]
Urethral cancer 2C93 Approved [2]
Urinary bladder neoplasm N.A. Approved [2]
Middle East Respiratory Syndrome (MERS) 1D64 Preclinical [5]
Severe acute respiratory syndrome (SARS) 1D65 Preclinical [5]
Colon cancer 2B90.Z Investigative [2]
Gemcitabine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Ribonucleoside-diphosphate reductase M2 (RRM2) TTBWDI0 RIR2_HUMAN Modulator [13]
------------------------------------------------------------------------------------
Gemcitabine Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [14]
Multidrug resistance-associated protein 5 (ABCC5) DTYVM24 MRP5_HUMAN Substrate [15]
Concentrative nucleoside transporter 1 (SLC28A1) DT0EQPW S28A1_HUMAN Substrate [16]
------------------------------------------------------------------------------------
Gemcitabine Interacts with 5 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytidine aminohydrolase (CDA) DEKEDRC CDD_HUMAN Metabolism [17]
Uridine/cytidine monophosphate kinase (UMPK) DEMPH4I KCY_HUMAN Metabolism [18]
Cytidine deaminase (cdd) DETX3A5 CDD_ECOLI Metabolism [19]
Cytidine deaminase (cdd) DEFVABT CDD_KLEP7 Metabolism [19]
Cytidine deaminase (cdd) DEYILK4 E0TLJ6_MYCHH Metabolism [20]
------------------------------------------------------------------------------------
Gemcitabine Interacts with 153 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Expression [21]
Ribonucleoside-diphosphate reductase large subunit (RRM1) OTXGQOR9 RIR1_HUMAN Affects Response To Substance [12]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [22]
NF-kappa-B inhibitor epsilon (NFKBIE) OTLAYEL9 IKBE_HUMAN Affects Expression [7]
Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B) OTQ4W7MT TR11B_HUMAN Increases Expression [7]
Stearoyl-CoA desaturase (SCD) OTB1073G SCD_HUMAN Increases Expression [7]
1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2) OT5I4Y9K PLCB_HUMAN Decreases Expression [7]
Insulin-induced gene 1 protein (INSIG1) OTZF5X1D INSI1_HUMAN Increases Expression [7]
E3 ubiquitin-protein ligase Praja-2 (PJA2) OT45TMC4 PJA2_HUMAN Increases Expression [7]
Interleukin-1 receptor-associated kinase-like 2 (IRAK2) OT6Y1QZN IRAK2_HUMAN Increases Expression [7]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Expression [7]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like (BNIP3L) OTJKOMXE BNI3L_HUMAN Increases Expression [7]
Heterogeneous nuclear ribonucleoprotein Q (SYNCRIP) OTRNDZXB HNRPQ_HUMAN Decreases Expression [7]
Melanoma-associated antigen C1 (MAGEC1) OTHMFHH8 MAGC1_HUMAN Increases Expression [7]
Liprin-alpha-4 (PPFIA4) OTWXG0DO LIPA4_HUMAN Increases Expression [7]
Transcription factor Maf (MAF) OT1GR3IZ MAF_HUMAN Increases Expression [7]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A) OTYG179K PR15A_HUMAN Increases Expression [7]
Krueppel-like factor 8 (KLF8) OTUC5CDB KLF8_HUMAN Increases Expression [7]
Fibrinogen gamma chain (FGG) OT5BJSEX FIBG_HUMAN Affects Expression [7]
Keratin, type II cytoskeletal 8 (KRT8) OTTM4X11 K2C8_HUMAN Decreases Expression [7]
Growth-regulated alpha protein (CXCL1) OT3WCTZV GROA_HUMAN Increases Expression [7]
Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) OTXOQDSG IFIT1_HUMAN Increases Expression [7]
Transcriptional activator Myb (MYB) OTJH64IV MYB_HUMAN Increases Expression [7]
Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3) OT2HZK5M GTR3_HUMAN Increases Expression [7]
Creatine kinase B-type (CKB) OTUCKOTT KCRB_HUMAN Decreases Expression [7]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Increases Expression [7]
Homeobox protein Hox-B2 (HOXB2) OTTD6HMV HXB2_HUMAN Increases Expression [7]
Methylated-DNA--protein-cysteine methyltransferase (MGMT) OT40A9WH MGMT_HUMAN Decreases Expression [7]
C-X-C motif chemokine 3 (CXCL3) OTSL94KH CXCL3_HUMAN Increases Expression [7]
Tumor necrosis factor alpha-induced protein 3 (TNFAIP3) OTVLI4DD TNAP3_HUMAN Increases Expression [7]
Diamine acetyltransferase 1 (SAT1) OT52AU22 SAT1_HUMAN Increases Expression [7]
Tumor necrosis factor receptor superfamily member 5 (CD40) OT5YU2XB TNR5_HUMAN Decreases Expression [7]
Protein EVI2B (EVI2B) OT98X1OE EVI2B_HUMAN Decreases Expression [7]
Heat shock 70 kDa protein 1-like (HSPA1L) OTC2V1K6 HS71L_HUMAN Decreases Expression [7]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [7]
Regulator of G-protein signaling 2 (RGS2) OT0FSRW7 RGS2_HUMAN Increases Expression [7]
Ras GTPase-activating-like protein IQGAP1 (IQGAP1) OTZRWTGA IQGA1_HUMAN Increases Expression [7]
Retinaldehyde dehydrogenase 3 (ALDH1A3) OT1C9NKQ AL1A3_HUMAN Increases Expression [7]
Max-interacting protein 1 (MXI1) OTUQ9E0D MXI1_HUMAN Increases Expression [7]
ETS translocation variant 1 (ETV1) OT6PMJIK ETV1_HUMAN Increases Expression [7]
Transcription initiation factor IIA subunit 1 (GTF2A1) OTWW4PN0 TF2AA_HUMAN Affects Expression [7]
Growth arrest-specific protein 1 (GAS1) OTKJXG52 GAS1_HUMAN Decreases Expression [7]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN) OTOWDUNT PTEN_HUMAN Affects Expression [7]
Ras-related protein Rab-8A (RAB8A) OTPB54Y3 RAB8A_HUMAN Decreases Expression [7]
Transforming growth factor beta-2 proprotein (TGFB2) OTC0TXEP TGFB2_HUMAN Increases Expression [7]
Large ribosomal subunit protein eL37 (RPL37) OTB6SDZ1 RL37_HUMAN Increases Expression [7]
Histone H4 (H4C1) OTB71W46 H4_HUMAN Decreases Expression [7]
C-C motif chemokine 20 (CCL20) OTUCJY4N CCL20_HUMAN Increases Expression [7]
Nuclear factor NF-kappa-B p100 subunit (NFKB2) OTS231V7 NFKB2_HUMAN Affects Expression [7]
Methylmalonate-semialdehyde/malonate-semialdehyde dehydrogenase , mitochondrial (ALDH6A1) OT8LCZCT MMSA_HUMAN Increases Expression [7]
Pro-neuregulin-1, membrane-bound isoform (NRG1) OTZO6F1X NRG1_HUMAN Increases Expression [7]
Tyrosine-protein phosphatase non-receptor type 11 (PTPN11) OTFH9M73 PTN11_HUMAN Affects Expression [7]
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1) OTG2T749 CP24A_HUMAN Decreases Expression [7]
ATP-dependent RNA helicase A (DHX9) OT5AAOQI DHX9_HUMAN Decreases Expression [7]
Nuclear cap-binding protein subunit 1 (NCBP1) OTYBR927 NCBP1_HUMAN Increases Expression [7]
TP53-binding protein 1 (TP53BP1) OTL8879S TP53B_HUMAN Increases Expression [7]
Ankyrin-3 (ANK3) OTJ3IRBP ANK3_HUMAN Increases Expression [7]
TNF receptor-associated factor 1 (TRAF1) OTTLM5RU TRAF1_HUMAN Affects Expression [7]
PDZK1-interacting protein 1 (PDZK1IP1) OTWA6M5K PDZ1I_HUMAN Increases Expression [7]
Treacle protein (TCOF1) OT4BOYTM TCOF_HUMAN Decreases Expression [7]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Affects Expression [7]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Increases Expression [7]
Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1) OTD1KRKO DYHC1_HUMAN Decreases Expression [7]
FXYD domain-containing ion transport regulator 3 (FXYD3) OT9PPRHE FXYD3_HUMAN Increases Expression [7]
Ankyrin repeat domain-containing protein 1 (ANKRD1) OTHJ7JV9 ANKR1_HUMAN Increases Expression [7]
Disks large homolog 2 (DLG2) OTQ3BD8U DLG2_HUMAN Increases Expression [7]
Cysteine and glycine-rich protein 2 (CSRP2) OT4SW0HI CSRP2_HUMAN Increases Expression [7]
Cyclin-G2 (CCNG2) OTII38K2 CCNG2_HUMAN Increases Expression [7]
Golgi-associated kinase 1B (GASK1B) OT2HPHEI GAK1B_HUMAN Decreases Expression [7]
SUZ domain-containing protein 1 (SZRD1) OTJMEJWT SZRD1_HUMAN Decreases Expression [7]
Leucine-rich repeat-containing protein 28 (LRRC28) OTFTT6VN LRC28_HUMAN Increases Expression [7]
Mitochondrial basic amino acids transporter (SLC25A29) OT09PIFE S2529_HUMAN Increases Expression [7]
Equilibrative nucleobase transporter 1 (SLC43A3) OTR60ZLA S43A3_HUMAN Decreases Expression [7]
E3 ubiquitin-protein ligase RNF149 (RNF149) OT6SBKQV RN149_HUMAN Increases Expression [7]
F-box only protein 25 (FBXO25) OTDFA7F4 FBX25_HUMAN Increases Expression [7]
Solute carrier family 2, facilitated glucose transporter member 14 (SLC2A14) OTBFIOVY GTR14_HUMAN Increases Expression [7]
Membrane progestin receptor beta (PAQR8) OTGZ8W9F PAQR8_HUMAN Increases Expression [7]
Nuclear receptor subfamily 4 group A member 3 (NR4A3) OTPBE9R1 NR4A3_HUMAN Increases Expression [7]
La-related protein 4B (LARP4B) OT2HI0QE LAR4B_HUMAN Increases Expression [7]
Collagen triple helix repeat-containing protein 1 (CTHRC1) OTV88X2G CTHR1_HUMAN Increases Expression [7]
BTB/POZ domain-containing protein KCTD12 (KCTD12) OTPYKT4Z KCD12_HUMAN Decreases Expression [7]
Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 (MAGI1) OTMV4ASV MAGI1_HUMAN Increases Expression [7]
Sialidase-1 (NEU1) OTH9BY8Y NEUR1_HUMAN Increases Expression [7]
Galactosylceramide sulfotransferase (GAL3ST1) OTSFFZRD G3ST1_HUMAN Decreases Expression [7]
Junctional adhesion molecule C (JAM3) OTX0F9QL JAM3_HUMAN Decreases Expression [7]
SLIT and NTRK-like protein 2 (SLITRK2) OTPVI22J SLIK2_HUMAN Increases Expression [7]
Anaphase-promoting complex subunit 1 (ANAPC1) OT2YY35L APC1_HUMAN Increases Expression [7]
Anthrax toxin receptor 1 (ANTXR1) OT5W1GPC ANTR1_HUMAN Affects Expression [7]
Ras-related GTP-binding protein D (RRAGD) OTXLVWAH RRAGD_HUMAN Increases Expression [7]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Affects Expression [7]
Intersectin-2 (ITSN2) OT8S0OO8 ITSN2_HUMAN Increases Expression [7]
Probable ribosome biogenesis protein RLP24 (RSL24D1) OT6KI56F RLP24_HUMAN Increases Expression [7]
Transcription elongation factor A protein-like 9 (TCEAL9) OT4UHDB5 TCAL9_HUMAN Increases Expression [7]
Chloride intracellular channel protein 4 (CLIC4) OT6KTPKD CLIC4_HUMAN Increases Expression [7]
Alpha-2-macroglobulin (A2M) OTFTX90K A2MG_HUMAN Increases Expression [8]
Stromelysin-1 (MMP3) OTGBI74Z MMP3_HUMAN Decreases Expression [8]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [8]
C-C motif chemokine 3 (CCL3) OTW2H3ND CCL3_HUMAN Increases Expression [8]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [8]
Kit ligand (KITLG) OTB9AVQ4 SCF_HUMAN Decreases Expression [8]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Expression [8]
Pappalysin-1 (PAPPA) OTTTG9PG PAPP1_HUMAN Decreases Expression [8]
Pro-interleukin-16 (IL16) OTZ2MO6B IL16_HUMAN Increases Expression [8]
Neurogenic locus notch homolog protein 1 (NOTCH1) OTI1WADQ NOTC1_HUMAN Increases Expression [23]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [24]
Nuclear protein 1 (NUPR1) OT4FU8C0 NUPR1_HUMAN Decreases Expression [25]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Decreases Expression [26]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [27]
Zinc finger protein GLI2 (GLI2) OTIRV97L GLI2_HUMAN Affects Expression [28]
CD44 antigen (CD44) OT9TTJ41 CD44_HUMAN Affects Expression [21]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [29]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [30]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Increases Phosphorylation [31]
Aryl hydrocarbon receptor nuclear translocator (ARNT) OTMSIEZY ARNT_HUMAN Increases Expression [28]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Increases Phosphorylation [31]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Increases Methylation [32]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Increases Expression [33]
Breast cancer type 1 susceptibility protein (BRCA1) OT5BN6VH BRCA1_HUMAN Increases Expression [28]
Dual specificity mitogen-activated protein kinase kinase 3 (MAP2K3) OTI2OREX MP2K3_HUMAN Increases Phosphorylation [34]
Dual specificity mitogen-activated protein kinase kinase 6 (MAP2K6) OTK13JKC MP2K6_HUMAN Increases Phosphorylation [34]
Serine/threonine-protein kinase PLK1 (PLK1) OTRZX45T PLK1_HUMAN Decreases Expression [28]
BH3-interacting domain death agonist (BID) OTOSHSHU BID_HUMAN Increases Cleavage [35]
POU domain, class 5, transcription factor 1 (POU5F1) OTDHHN7O PO5F1_HUMAN Decreases Expression [21]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Increases Expression [36]
Regenerating islet-derived protein 3-alpha (REG3A) OT0BVQRB REG3A_HUMAN Decreases Expression [37]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [31]
Protein patched homolog 1 (PTCH1) OTMG07H5 PTC1_HUMAN Affects Expression [28]
Sonic hedgehog protein (SHH) OTOG2BXF SHH_HUMAN Decreases Expression [28]
Tumor protein p53-inducible nuclear protein 1 (TP53INP1) OT2363Z9 T53I1_HUMAN Increases Expression [37]
Protein smoothened (SMO) OTXXE208 SMO_HUMAN Increases Expression [33]
Homeobox protein NANOG (NANOG) OTUEY1FM NANOG_HUMAN Decreases Expression [33]
Axin-2 (AXIN2) OTRMGQNU AXIN2_HUMAN Affects Expression [28]
3',5'-cyclic-AMP phosphodiesterase 4D (PDE4D) OT1RWFV0 PDE4D_HUMAN Increases ADR [38]
Splicing factor 45 (RBM17) OT9ROJCL SPF45_HUMAN Decreases Response To Substance [39]
Oxysterol-binding protein 2 (OSBP2) OTDGLB4J OSBP2_HUMAN Increases ADR [38]
Proto-oncogene tyrosine-protein kinase Src (SRC) OTETYX40 SRC_HUMAN Decreases Response To Substance [40]
Equilibrative nucleoside transporter 3 (SLC29A3) OTGLX8XU S29A3_HUMAN Affects Transport [41]
Probable ATP-dependent RNA helicase DDX53 (DDX53) OTHK3EGZ DDX53_HUMAN Affects Response To Substance [42]
Equilibrative nucleoside transporter 1 (SLC29A1) OTLOOZZS S29A1_HUMAN Increases Response To Substance [43]
Alpha-protein kinase 3 (ALPK3) OTLUYSMO ALPK3_HUMAN Increases ADR [38]
Transcription factor AP-2-alpha (TFAP2A) OTMYT3NK AP2A_HUMAN Increases Response To Substance [44]
Death-associated protein kinase 1 (DAPK1) OTNCNUCO DAPK1_HUMAN Increases ADR [45]
Cytochrome c oxidase subunit 3 (COX3) OTNNGBYJ COX3_HUMAN Decreases Response To Substance [46]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Decreases Response To Substance [47]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Increases ADR [48]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Affects Response To Substance [49]
Serine/threonine-protein kinase SMG1 (SMG1) OTTS3SXE SMG1_HUMAN Decreases Response To Substance [50]
ATP-dependent DNA helicase PIF1 (PIF1) OTUHKKVP PIF1_HUMAN Decreases Response To Substance [29]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Decreases Response To Substance [51]
Ribonucleoside-diphosphate reductase large subunit (RRM1) OTXGQOR9 RIR1_HUMAN Increases ADR [52]
Olfactory receptor 4D6 (OR4D6) OTXJKUT1 OR4D6_HUMAN Affects Response To Substance [42]
PDZ domain-containing protein GIPC1 (GIPC1) OTXLVCPJ GIPC1_HUMAN Affects Response To Substance [53]
Poly polymerase 2 (PARP2) OTYL81ZI PARP2_HUMAN Decreases Response To Substance [54]
------------------------------------------------------------------------------------
⏷ Show the Full List of 153 DOT(s)
Indication(s) of PHA848125
Disease Entry ICD 11 Status REF
Thymic cancer 2C27 Phase 2 [6]
PHA848125 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Cyclin-dependent kinase 2 (CDK2) TT7HF4W CDK2_HUMAN Inhibitor [55]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 Gemcitabine FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4793).
5 Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7938).
7 Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat. 2007 Apr;102(2):157-72.
8 Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer. 2010 Jun 29;103(1):52-60.
9 Gemcitabine induces the VMP1-mediated autophagy pathway to promote apoptotic death in human pancreatic cancer cells. Pancreatology. 2010;10(1):19-26. doi: 10.1159/000264680. Epub 2010 Mar 19.
10 XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics. Pancreas. 2006 Apr;32(3):288-96. doi: 10.1097/01.mpa.0000218314.67111.fb.
11 Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer. 2008 Sep 2;99(5):760-7. doi: 10.1038/sj.bjc.6604528.
12 14-3-3 regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression. Oncotarget. 2016 Apr 5;7(14):17726-36. doi: 10.18632/oncotarget.7394.
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
14 Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 2003 Jun 16;88(12):1963-70.
15 Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia. 2010 Sep;12(9):740-7.
16 Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers (Basel). 2017 Nov 16;9(11).
17 Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. Br J Clin Pharmacol. 2011 Mar;71(3):437-44.
18 Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab Dispos. 2008 Sep;36(9):1951-9.
19 Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017 Sep 15;357(6356):1156-1160.
20 Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9.
21 Deregulation of the CD44-NANOG-MDR1 associated chemoresistance pathways of breast cancer stem cells potentiates the anti-cancer effect of Kaempferol in synergism with Verapamil. Toxicol Appl Pharmacol. 2022 Feb 15;437:115887. doi: 10.1016/j.taap.2022.115887. Epub 2022 Jan 19.
22 Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis. Oncol Rep. 2007 Sep;18(3):523-9.
23 Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther. 2011 Jan;19(1):188-95.
24 Targeting PKM2 improves the gemcitabine sensitivity of intrahepatic cholangiocarcinoma cells via inhibiting -catenin signaling pathway. Chem Biol Interact. 2024 Jan 5;387:110816. doi: 10.1016/j.cbi.2023.110816. Epub 2023 Nov 22.
25 p8 is a new target of gemcitabine in pancreatic cancer cells. Clin Cancer Res. 2006 Jan 1;12(1):235-41. doi: 10.1158/1078-0432.CCR-05-1700.
26 The anthelmintic drug niclosamide induces GSK--mediated -catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression. Cell Death Dis. 2022 Feb 3;13(2):112. doi: 10.1038/s41419-022-04573-7.
27 Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene. 2007 May 17;26(23):3431-9. doi: 10.1038/sj.onc.1210129. Epub 2006 Dec 4.
28 A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther. 2010 Feb;9(2):311-8. doi: 10.1158/1535-7163.MCT-09-0693. Epub 2010 Jan 26.
29 Petite Integration Factor 1 knockdown enhances gemcitabine sensitivity in pancreatic cancer cells via increasing DNA damage. J Appl Toxicol. 2023 Oct;43(10):1522-1532. doi: 10.1002/jat.4494. Epub 2023 May 16.
30 Gemcitabine-induced apoptosis in 5637 cell line: an in-vitro model for high-risk superficial bladder cancer. Anticancer Drugs. 2007 Feb;18(2):179-85. doi: 10.1097/CAD.0b013e328010ef47.
31 Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004 Oct 19;502(3):169-83. doi: 10.1016/j.ejphar.2004.09.006.
32 Reversible epigenetic regulation of 14-3-3 expression in acquired gemcitabine resistance by uhrf1 and DNA methyltransferase 1. Mol Pharmacol. 2014 Nov;86(5):561-9. doi: 10.1124/mol.114.092544. Epub 2014 Sep 4.
33 Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44. doi: 10.1073/pnas.1424171112. Epub 2015 Jan 20.
34 Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells. Biochem Biophys Res Commun. 2004 Mar 26;316(1):71-7. doi: 10.1016/j.bbrc.2004.02.017.
35 Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer. 2004 Mar 20;109(2):182-8. doi: 10.1002/ijc.11679.
36 Gemcitabine combined with gum mastic causes potent growth inhibition and apoptosis of pancreatic cancer cells. Acta Pharmacol Sin. 2010 Jun;31(6):741-5. doi: 10.1038/aps.2010.54.
37 Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells. World J Gastroenterol. 2006 Mar 14;12(10):1597-602. doi: 10.3748/wjg.v12.i10.1597.
38 Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug;104(8):1074-82. doi: 10.1111/cas.12186. Epub 2013 Jun 10.
39 Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res. 2005 Aug 1;65(15):6593-600. doi: 10.1158/0008-5472.CAN-03-3675.
40 Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 2004 Apr 1;10(7):2307-18.
41 Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G910-22. doi: 10.1152/ajpgi.90672.2008. Epub 2009 Jan 22.
42 Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities. Clin Cancer Res. 2016 Jan 15;22(2):366-73. doi: 10.1158/1078-0432.CCR-15-0964. Epub 2015 Sep 16.
43 Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. Lab Invest. 2008 Jul;88(7):773-84. doi: 10.1038/labinvest.2008.40. Epub 2008 May 19.
44 Increased expression of transcription factor TFAP2 correlates with chemosensitivity in advanced bladder cancer. BMC Cancer. 2011 Apr 14;11:135. doi: 10.1186/1471-2407-11-135.
45 A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy. Pharmacogenet Genomics. 2012 Apr;22(4):229-35. doi: 10.1097/FPC.0b013e32834e9eba.
46 An increase of cytochrome C oxidase mediated disruption of gemcitabine incorporation into DNA in a resistant KB clone. Biochem Pharmacol. 2007 Jun 15;73(12):1927-38. doi: 10.1016/j.bcp.2007.03.014. Epub 2007 Mar 20.
47 Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol. 2011 Sep;122(3):641-7. doi: 10.1016/j.ygyno.2011.05.003. Epub 2011 Jun 8.
48 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
49 Triplex-forming oligonucleotides targeting c-MYC potentiate the anti-tumor activity of gemcitabine in a mouse model of human cancer. Mol Carcinog. 2014 Sep;53(9):744-52. doi: 10.1002/mc.22026. Epub 2013 May 16.
50 [Effect of inhibiting the expression of hSMG-1 on chemosensitivity of human non-small cell lung cancer H1299 cells]. Zhonghua Yi Xue Za Zhi. 2011 Mar 1;91(8):554-9.
51 A novel 3-dimensional culture system uncovers growth stimulatory actions by TGF in pancreatic cancer cells. Cancer Biol Ther. 2011 Aug 1;12(3):198-207. doi: 10.4161/cbt.12.3.15979. Epub 2011 Aug 1.
52 An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. Oncologist. 2007 Jun;12(6):622-30. doi: 10.1634/theoncologist.12-6-622.
53 GAIP interacting protein C-terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathways. PLoS One. 2014 Dec 3;9(12):e114409. doi: 10.1371/journal.pone.0114409. eCollection 2014.
54 Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010 Oct 15;70(20):7970-80. doi: 10.1158/0008-5472.CAN-09-4521. Epub 2010 Aug 26.
55 Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.